Cost-effectiveness of nivolumab in patients with NSCLC in the United States

To determine the lifetime cost-effectiveness of nivolumab vs docetaxel in advanced squamous and nonsquamous non-small cell lung cancer (NSCLC) following platinum-based chemotherapy from a US payer perspective. Trial- and cohort-based cost-effectiveness analyses. The analyses used partitioned surviva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of managed care 2021-08, Vol.27 (8), p.e254-e260
Hauptverfasser:	Chaudhary, Mohammad A, Lubinga, Solomon J, Smare, Caitlin, Hertel, Nadine, Penrod, John R
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical trials Cost analysis Cost-Benefit Analysis Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Metastasis Middle Aged Monoclonal antibodies Nivolumab - therapeutic use Patients Quality-Adjusted Life Years Regulatory approval Survival analysis Targeted cancer therapy United States Willingness to pay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!